TABLE 2

Characteristics of patients classified by remission 7.5, remission 6.5, and improved C-peptide secretion

nSex (male/female)Age (years)BMI percentilepHA1C (%)C-peptide (pmol/l)
Patients in remission 7.58941/489.9 (6.7–12.5)71.2 (45.6–87.8)*7,390 (7.350–7.410)*8.5 (7.6–9.3)*522 (250–818)*
Patients not in remission 7.516187/749.4 (5.4–11.3)52.7 (26.8–75.3)7,350 (7.250–7.400)9.1 (8.3–9.99)355 (230–516)
Patients in remission 6.54618/2810.8 (7.8–13.5)74.4 (48.3–87.8)7,385 (7.291–7.410)8.2 (7.2–9.1)*529 (226–945)
Patients not in remission 6.5204110/949.3 (5.8–11.3)55.8 (29.4–76.9)7,370 (7.280–7.400)9.0 (8.3–9.8)375 (231–559)
Patients with improved C-peptide secretion2715/1210.2 (5.9–13.1)62.8 (48.3–87.8)7,380 (7.250–7.405)9.1 (7.8–9.6)392 (238–787)
Patients without improved C-peptide secretion200101/999.5 (6.4–11.5)58.2 (31.8–79.3)7,365 (7.285–7.400)8.9 (8.2–9.9)410 (230–586)
  • Data are median (interquartile range). Due to incomplete data record for classification, 22 patients for both definitions of remission and 45 patients for improved C-peptide secretion were excluded from analysis. For sex, absolute numbers are given. Sex, age, and pH have been determined at diagnosis and BMI percentiles, A1C, and C-peptide 1 month after diagnosis. Dichotomous variables and variables with non-Gaussian distribution were compared within the classification using Fisher’s exact test and Mann-Whitney tests, respectively.

  • * P < 0.001,

  • P < 0.05,

  • P < 0.01. Statistically significant correlations are indicated in bold.